Apriligen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Apriligen is a private, pre-revenue biotech founded in 2021 and based in San Diego, focused on developing curative gene therapies for rare pediatric diseases. Its lead candidate, APR-2020, has received multiple regulatory designations (Orphan Drug, Fast Track, Rare Pediatric Disease, RDEP) from the FDA and EMA, with an IND cleared and Phase 1 trials set to begin in Q1 2026. The company's autologous lentiviral vector platform offers a potentially less toxic alternative to bone marrow transplant for DBA and could be expanded to other monogenic illnesses.

Rare Pediatric DiseasesHematologyGenetic Disorders

Technology Platform

Proprietary lentiviral vector platform for ex vivo autologous gene therapy, initially targeting monogenic hematologic diseases like Diamond Blackfan Anemia.

Opportunities

APR-2020 addresses a high-unmet need in an ultra-rare disease with no approved pharmacotherapy, supported by accelerated regulatory pathways.

Successful validation in DBA creates a platform for expansion into other monogenic pediatric hematologic and metabolic diseases, leveraging the same core lentiviral vector technology.

Risk Factors

Key risks include clinical safety (e.g., insertional mutagenesis), efficacy uncertainty, and the immense complexity and cost of manufacturing autologous ex vivo gene therapies.

Commercial risks involve patient identification and reimbursement challenges for a potential one-time multi-million dollar therapy in a tiny patient population.

Competitive Landscape

Direct competition is limited; the main current alternative is allogeneic bone marrow transplant. However, Apriligen may face future competition from other gene therapy or gene editing (e.g., CRISPR/Cas9) approaches targeting DBA or similar monogenic disorders. The competitive intensity is currently low but may increase as the platform's potential is demonstrated.

More companies in Cell & Gene Therapy →More companies in United States →